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Abstract
Rabies, despite available vaccines, causes approximately 55,000 deaths every 
year. Diagnosing relies on noting physical behaviors such as hydrophobia, vomit-
ing, fever, behavior changes, paralysis, and consciousness, as well as, using several 
methodologies to molecularly detect the presence of the virus. RABV often enters 
through a bite wound given that it is transmissible through saliva. Infection spreads 
from muscle fibers into the peripheral nervous system traveling to the central 
nervous system. Infection of the central nervous system can lead to encephalitis 
(furious rabies) or acute flaccid paralysis (paralytic rabies). Treatment relies heav-
ily on the time of exposure. If the patient is diagnosed prior to being symptomatic, 
post-exposure prophylaxis (PEP) can be administered. However, once the patient 
has begun displaying symptoms, therapy success rates sharply decline. Prevention 
includes vaccinating during both pre- and post-exposures, as well as utilizing 
Stepwise Approach towards Rabies Elimination (SARE) to aid impoverished 
countries in declining their rabies mortality rates.
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1. Introduction
Rabies, an RNA virus from the genus Lyssavirus, also known as RABV, is a lethal 
pathogen to several species [1]. The evolutionary history of the virus suggests that 
its most recent ancestor likely diverged into two descendants, one infecting bats, the 
other infecting dogs. Once domesticated dogs became infected in the Old World, 
humans became the next target. Evolutionary biology tells us that rabies likely did 
not exist in the New World prior to the settlement of Europeans but was common 
throughout Europe, Asia, and Africa well before the discovery of the Americas [2].
RABV is transmitted through the saliva of an infected individual into the 
bloodstream of a healthy individual, typically via a bite, but possible through other 
wounds or ocular route. Upon infection, there are two ways the virus may manifest: 
furious and paralytic. Furious rabies often presents itself with bouts of anxiety, irri-
tability, phobias, and many other symptoms that will later be discussed. Paralytic 
rabies has some common symptoms with furious rabies, however, paralysis is the 
most notable symptom just prior to death [3].
According to the CDC in 2015, nearly 60,000 human deaths occurred on 
average each year. Statistically, this can be interpreted as 1 human death every nine 
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minutes [4]. Despite its large impact globally, the virus is relatively diminutive. The 
rabies virus has evolutionarily reduced its single-stranded RNA genome to only 
five genes. These genes encode five proteins, three of which make up the ribonu-
cleoprotein (RNP) complex; the other two form the virus’s envelope [5].
While the rabies virus has been heavily researched, lives continue to be lost. 
There is a great understanding of the epidemiology of the virus, however little is 
understood about the pathogenesis. Herein, the findings regarding the diagnosis, 
clinical course, treatment, and prevention of the rabies virus are summarized as 
well as data gaps in research and understanding of this pathogen.
2. Diagnostics
Once the patient has become infected, the incubation period can be as short 
as 5 days or as long as 2 years. However, it is common for symptoms to occur 
20–90 days after initial exposure [6]. Nevertheless, there are several techniques for 
diagnosing a patient during and after the incubation period.
2.1 Physical symptoms
As mentioned previously, the two ways the rabies virus may present itself is 
paralytic and furious symptoms. A patient with paralytic rabies will show progres-
sive paralysis until death. If infection occurred due to a bite, the paralysis typi-
cally starts around the wounded area, spreading outwards. It is also common for 
patients to have a fever, vomiting, weakness in muscles, and myalgia prior to the 
paralysis [7].
Furious rabies often presents itself with more obvious symptoms. The 
infected individual commonly displays mood swings, unregulated consciousness, 
phobias, especially hydrophobia, as well as spasms of the respiratory system  
[1, 8]. Other symptoms may include a cough, psychosis, delirium, and difficul-
ties swallowing [9].
2.2 Neuroimaging
For both furious and paralytic rabies, magnetic resonance imaging (MRI) will 
produce the same key diagnostic images. When symptoms first arise in the prodro-
mal phase, progression in hypersignal T2 changes can be seen around the brachial 
plexus and the spinal nerve roots associated with the extremity of infection origin. 
The main MRI feature is increased T2 signal (seen on T2 and FLAIR sequences) in 
the affected parts of the brain and spinal cord, with a predilection for grey matter 
structures including basal ganglia, thalami, hypothalami, limbic system, and brain-
stem. The abnormal hypersignal T2 changes will continue to progress as the patient 
enters a coma. Once in the comatose phase, the contrast will enhance around the 
spinal cord, nerve roots located at the sine and cranial region, deep grey matter, 
brain stem, limbic structures, and thalamus (Figure 1) [8].
Another study noted that lesions could be seen throughout different areas of the 
neuroaxis. They, too, found that paralytic and furious rabies present the same MRI 
indications, however, they are more noticeable in the paralytic form. The blood–
brain barrier often shows no sign of damage until the patient reaches the comatose 
state. Imaging of the blood–brain barrier has greatly improved as new techniques 
such as diffusion-weighted and diffusion tensor imaging can capture objective and 
subjective data [11].
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2.3 Testing techniques
There are several techniques used to diagnose a patient with a rabies infec-
tion; including reverse transcription polymerase chain reaction (rtPCR) analysis, 
fluorescent antibody test (FAT), tissue culturing, and viral antibody neutralization 
[12, 13]. The FAT assay has long been a microbiological standard for diagnosing 
rabies (and other viral infections). Fluorescent antibody virus neutralisation 
(FAVN) test is also used to diagnose rabies [13]. The CDC recommends a direct 
form of FAT to detect the rabies virus in animals ante-mortem, however, the 
animal is usually euthanized after detection and brain tissue samples taken to 
solidify the diagnosis post-mortem. However, diagnosis in humans requires several 
different types of methods such as direct rapid immunohistochemistry testing, the 
use of electron microscopy, and reverse transcriptase-polymerase chain reactions 
on biological samples (Figure 2) [14].
Another test utilizing immunohistochemistry, known as the direct rapid immu-
nohistochemistry test (dRIT) is a specific form of histology because it employs 
antibodies unique to RABV. While this testing method can give a reliable result in 
less than an hour, retrieving brain samples is very invasive [16].
Samples can also be viewed using electron microscopy. When Negri bodies are 
located in samples, electron miscopy can give a clear depiction of the bullet-shaped 
Figure 1. 
Magnetic resonance images with arrows pointing to high focal areas (A. dorsal medulla, B. pons, C.  
hypothalamus, and D. splenium of corpus callosum) of an infected patient with furious rabies [10].
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rabies virus being produced. A colloid can be used to compare the virus size to 
further interpret the image, however shape and size alone are not enough to identify 
with confidence [17].
Saliva and skin samples can be used for identifying the presence of RABV. rtPCR 
can be used to confirm or oppose the results of FAT test results. Because RABV is 
a single-stranded RNA virus, rtPCR can help transform RNA into DNA through 
amplification for analysis of a complement to a rabies-specific primer. This is often 
achieved by inoculating suckling mice and retrieving brain or kidney samples after 
death [14, 18].
2.4 Patients with psychiatric disorders
Given that the rabies virus significantly impacts the central nervous system, it is 
not uncommon for hallucinations, manic episodes, anxiety, and bouts of paranoia 
to be present in an infected patient [19, 20]. However, these are also common symp-
toms of psychiatric disorders such as schizophrenia. While it is rare, it is possible 
that correct RABV diagnosis may be complicated by a previous diagnosis of psychi-
atric disorders. Patients suffering from hypochondriasis could elicit psuedorabies 
[20]. In several case studies with reports of hypochondriasis, patients did not 
respond to therapies and often attempt suicide multiple times [20, 21]. While these 
situations are rare, they should be noted when diagnosing patients with certainty.
3. Clinical course
3.1 Pathophysiology
The most common entry point for RABV is through the bite of an infected 
individual as rabies resides in saliva [22]. However, transmission from organ 
transplants and aerosol droplets have also been recorded [23–25]. Upon entry, 
an incubation period often takes place in the myocytes, and rarely fibrocytes, 
where the virus attaches to the G-protein of the cells, enters through pinocytosis 
or fusion, and replicates in the cytoplasm of the cells [5, 24]. Virions will replicate 
with little to no immune response until the virus interacts with and infects a nerve 
cell. The rabies virus gains access to the nervous system by binding to the nicotinic 
acetylcholine receptors on the postsynaptic membrane at the neuromuscular 
junction [26]. From the point of nerve cell infection, the virus will travel via axon 
transport through the nervous system, eventually reaching the brainstem to give 
rise to either encephalitis or acute flaccid paralysis [7, 27]. The incubation periods 
are highly variable depending on the dosage of the virus. However, in humans, the 
incubation period is often >1–3 months. Canine incubation periods are most com-
monly less than 60 days [26, 28].
Figure 2. 
These images show the comparison of a positive direct FAT result (left) and a negative direct FAT result 
(right) [15].
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Once infection is recognized by the immune system, cytokine, IgM, and IgG 
antibody production increases [5]. Specific cytokines, Interleukin-1β (IL-1β) and 
TNFα, are thought to be the reason inflammation of the central nervous system 
occurs post-exposure [29]. The presence of these cytokines initiate a cascade 
reaction, upregulating proteins necessary for the inflammatory response such as 
the major histocompatibility complex and adhesion molecules. These proteins then 
interact with leukocytes to allow the blood brain barrier to become more perme-
able, thus causing an immune response leading to encephalitis [30]. As for the natu-
ral defense against rabies, RABV signals a series of molecular cascades that initiates 
type I interferon responses that have antiviral properties, decreasing the pathoge-
nicity of rabies [31]. However, to artificially aid the natural response, there is heavy 
research on the potential to activate dendritic cells which subsequently enhance the 
activity of interleukin proteins and high mobility group box 1 (HMBG1) to enhance 
immunogenicity [32, 33].
4. Treatment
Although the rabies disease has been documented for thousands of years, it is still 
largely considered incurable after the onset of symptoms [34]. This is due to the small 
window of time during which aggressive treatment is practical and effective. With 
that knowledge, most often treatment resolves to be mostly palliative with aggressive 
treatment proving to be essentially ineffective after RABV is established in the patient.
4.1 Aggressive approach
If a patient presents for treatment early in the process of the clinical disease, 
the choice may be made to apply an aggressive approach. At this point, the patient 
must be immediately admitted to an intensive care hospital and post-exposure 
prophylaxis (PEP) should be administered [26]. PEP consists of immediate washing 
of the wound with soap and water, a post-exposure vaccination, and injection of an 
anti-rabies immunoglobulin (RIG) directly into the wound [35].
Active immunization has evolved greatly since the first rabies vaccine was 
developed and administered in 1885 [36, 37]. Louis Pasteur is credited with this first 
vaccine that consisted of injecting the patient with homogenates of RABV-infected 
rabbit spinal cord multiple times over a period of days. The initial injection was 
believed to be fully inactivated after an extended desiccation period, and each 
subsequent inoculation was increasingly more virulent as the desiccation period was 
decreased. While this was found to be somewhat effective, two major issues pre-
sented themselves. First, the inactivation of the RABV was inconsistent which led to 
some patients becoming infected after receiving the vaccine. Second, there was an 
inequity in the supply of the RABV-infected rabbits and the demand of the human 
population. These were rectified with the introduction of RABV-infected sheep 
and goat brain vaccines [36, 37]. These new vaccines were inactivated via chemical 
agents such as phenol; this proved to be much more consistent. However, soon it 
was understood that vaccines produced from mature brain material contained an 
excess of myelin which caused sensitization and ultimately killed the patients [38]. 
From this discovery emerged the current methodology by which rabies vaccines are 
created. Chick embryos served the same role as the previous tissues, but they have 
markedly less myelin due to the young age [39]. The same can be said of the lines of 
human diploid cells infected with fixed RABV for vaccines [36, 37]. In the United 
States, there are two CDC-approved vaccines: the human diploid cell culture vac-
cine (HDCV) and the purified chick embryo cell culture vaccine (PCECV) [14].
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The post-exposure vaccine is primarily an intramuscular vaccine that ought to 
be given on day 0, 3, 7, 14, and 30 [36]. An intradermal vaccine has recently been 
developed in an attempt to decrease the amount of vaccine needed per injection 
[40]. While the decreased cost of the vaccine is an attractive option, intradermal 
injections are generally considered more difficult which could decrease the effec-
tiveness of the vaccine due to improper injections. The World Health Organization 
(WHO) strongly recommends purified cell culture and embryonated egg-based 
vaccines [41].
Although the vaccines have been proven to stimulate an appropriate immune 
response to RABV, this immune response is often too delayed to prevent the virus 
from entering the nerves [42]. With this knowledge, passive immunization is 
recommended for all patients that have no previous history with the disease or a 
pre-exposure vaccination. At this time, two types of rabies immunoglobulin are 
available – human rabies immunoglobulin (HRIG) and equine rabies immuno-
globulin (ERIG). These have been used since the 1970’s to temporarily increase the 
concentration of rabies virus neutralizing antibodies (RVNA) specifically at the 
site of exposure [43]. If the patient has multiple bites or wounds, the RIG needs to 
be applied at each site to be effective [44]. HRIG is to be administered at a dosage 
or 20 IU/kg while the recommended dosage for ERIG is 40 IU/kg [42, 44]. Due 
to higher odds of sensitization as well as quicker elimination of the RVNA, HRIG 
is generally the most preferred option for passive immunization. However, it is 
approximately five times more expensive than ERIG. This results in a major defi-
ciency in many of the countries most in need of rabies treatment [44].
Because the available RIGs are generally inaccessible to developing countries, 
WHO encouraged researchers to pursue synthetization of a human monoclonal 
antibodies (mAbs) cocktail that can be used to treat rabies [45]. At this time, 
there are a number of rabies mAbs products in clinical trials, but none have been 
approved by the US Food and Drug Administration [46]. In 2018, WHO officially 
adjusted their recommendations for treatment of rabies to include mAbs products 
in place of RIG if available [46].
A protocol known as the Milwaukee Protocol was presented as a potential cure in 
the late 20th century, but it has since been proven to be inconsistent and generally 
ineffective in reverting or curing the patient of the disease [47–49]. This protocol 
consisted of an induced coma and one or more antivirals. The coma was soon deter-
mined to be ineffective. It is now recommended that sedation should be limited to 
prevent the use of ventilatory support if possible [48, 49].
Antivirals could serve an important role in the treatment of the rabies virus 
as they act as inhibitors of viral replication. An effective antiviral could slow the 
progression of the rabies virus enough for the patient’s innate immune response 
to develop and react appropriately. However, at this time, there are few antivirals 
supported for the treatment of RABV. Ribavirin is a purine analogue that acts as an 
RNA mutagen and has shown to be clinically effective for multiple viruses including 
Hepatitis C and Lassa fever virus [50, 51]. Despite its inclusion in the sporadically 
effective Milwaukee Protocol, it has repeatedly proven to be ineffective against the 
rabies virus. Interferon-α (IFN-α) is a signaling protein used to trigger an immune 
response which has been shown to limit RABV spreading in mice trials [50, 51]. 
However, additional trials in which primates were administered intramuscular 
and intrathecal IFN-α determined the effects of immediate inoculation to be 
incomplete while the effects of delayed inoculation were nonexistent [52, 53]. Six 
human patients have been treated with IFN-α on two different dosage schedules 
and despite evidence of increased IFN in serum and CSF, there was no evidence of 
a beneficial effect on the disease itself [54]. Another therapy previously included in 
the Milwaukee Protocol is ketamine [50, 51]. At low concentrations, approximately 
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1 μM, ketamine works as a non-competitive antagonist of the N-methyl-D-aspartate 
(NMDA) receptor which causes a state of dissociative anesthesia. A study from 1991 
showed that a high concentration of ketamine could induce inhibitory effects on 
the RABV genome transcription [55]. Since that time, multiple other trials using 
neuron cultures and infected mice have produced evidence that ketamine is gener-
ally ineffective against the disease [56]. With that knowledge, it is believed that 
ketamine should not be used for treatment of the rabies virus until further studies 
produce more promising results. Amantadine is the third and final antiviral that 
was considered in the Milwaukee Protocol [47, 51]. It is a synthetic inhibitor of 
viral replication by impeding the release of viral genetic material into the host cell. 
Although amantadine demonstrated some interference in cellular trials, it failed in 
animal trials [57]. Minocycline, a broad spectrum antimicrobial, was considered for 
RABV treatment as it has proven benefits for multiple other viruses [58]. However, 
when applied to rabies-infected animals, Minocycline caused a number of harmful 
effects causing an increase in mortality [59].
More recently, researchers have addressed the use of favipiravir in treatment 
of rabies [50]. Available for influenza treatment in some countries, favipiravir 
has shown some activity against the rabies virus in mice trials [60]. Continued 
studies are needed to assess the future of this and other antivirals. It ought to 
be noted that despite variations in the effectiveness of these antivirals, all have 
shown that an early start of treatment greatly improves the efficacy of these 
therapies.
4.2 Palliative care
As previously mentioned, there is a small window of effectiveness for an aggres-
sive treatment of RABV; after that window has passed, the focus of treatment is 
purely one of comfort for the patient. Many patients develop phobias that will 
likely require seclusion in a calm, quiet room. Although there is little to no evidence 
of human-to-human transmission, visitors and medical professionals need to be 
cautious of potential contamination via the patient’s secretion [61]. Dehydration 
is a major concern as paralytic rabies often inhibits the patient’s ability to swallow 
and furious rabies can cause intense hydrophobia. Treatment for the dehydration is 
typically a secured intravenous line. If additional nutrients are needed, they can be 
administered through the same line.
Rabies typically causes a generalized inflammation that induces a fever, but it 
can also trigger a neurogenic (central) fever as well [62]. Many antipyretics, such as 
acetaminophen and ibuprofen, have been successfully used to treat the generalized 
fever. However, those are generally ineffective towards the central fever. There is 
some evidence to support the use of baclofen, bromocriptine, chlorpromazine, and 
morphine in the treatment of a central fever [63]. However, these have not been 
studied specifically for a rabies-induced central fever and so practitioners should 
be mindful of potential side effects. Additionally, these drugs are rarely available in 
the developing countries where RABV is most prevalent [61]. In this case, external, 
physical means of cooling the patient can be used as needed.
The majority of patients infected with furious RABV develop intense agitation 
and fear. A variety of sedatives and tranquilizers are used to calm these symptoms. 
Because benzodiazepines are included on the WHO’s list of essential medicines, 
they are commonly used to treat rabies-induced agitation as well as many other 
forms [61]. They can be administered intramuscularly, intravenously, or intrarec-
tally as needed. However, as previously mentioned, it is important to administer 




Lastly, clinicians will likely need to address the patient’s pain level. This can be 
accomplished using opioids such as morphine or other highly effective analgesics. 
These can be delivered intravenously, intramuscularly, intrarectally, or even 
transdermally as needed [61]. Although many of these methods of treatment are 
expensive and generally unlikely to cure a patient once rabies symptoms are pres-
ent, palliative care is a responsibility of caretakers and clinicians.
5. Prevention
Due to the general ineffectiveness of post-exposure treatment, the rabies 
virus has a remarkably high mortality rate despite the availability of vaccines 
that have shown a near perfect success rate when administered prior to infection. 
This indicates that the main issue with prevention is the lack of accessibility 
in the impoverished countries of Asia and Africa. In 2015, the World Health 
Organization (WHO) and the World Organization for Animal Health (OIE) 
with the help of the Food and Agriculture Organization of the United Nations 
(FAO) set a goal to rid the world of dog-mediated rabies by 2030 (Zero by 30) 
[65]. After assessing cost and general accessibility, it was decided that the best 
way to eliminate dog-mediated rabies is to vaccinate dogs rather than humans. 
Vaccinating at least 70% of dogs should effectively break the cycle of rabies 
transmission.
To reach this goal, WHO, OIE, FAO and many smaller agencies collaborated 
to create the Stepwise Approach towards Rabies Elimination (SARE) [66, 67]. 
A similar stepwise approach proved successful in the elimination of fox RABV 
from Europe [68]. SARE consists of five stages for each country to work through. 
Stage 0 is simply the lack of information and data on RABV cases in a country 
where rabies is believed to be present. Stage 1 is an assessment phase in which 
data are gathered to determine the extent to which RABV pervades the country 
of interest. During this phase, the government assesses the current guidelines or 
structures in place as well as collects and analyzes all available data on previous 
or existing RABV cases. The beginning of an action plan is usually concocted in 
Stage 1. Evolution of this plan happens in Stage 2; it is important to develop an 
understanding of the available funding at this point as that has been the biggest 
limitation for developing countries in the past. Stage 3 is the implementation of 
the country’s rabies control strategy. During this phase, the plan will likely need 
to be adapted to address any challenges that arise; these may include the exposure 
of wildlife reservoirs of RABV such as the fox rabies previously found in Europe. 
When reported human cases have decreased to zero, the country will shift into 
Stage 4 – elimination of dog RABV. This requires the maintenance of the reduced 
dog-to-human rabies transmission as well as continued implementation of the 
action plan to continue to reduce dog rabies cases. Lastly, in Stage 5, the country 
must develop a post-elimination strategy to maintain the freedom from human 
and dog rabies.
While the SARE tool has been developed to be adaptable enough to suc-
ceed worldwide, there are likely to be some setbacks in the different landscapes. 
Specifically, areas of poverty will be constrained by the financial resources they 
can acquire. Many parts of Asia have political instability that will greatly challenge 
the need for nation-wide commitment to this goal. Similarly, Africa’s linguistic and 
cultural complexity will oppose the need for excellent communication and tracking 
[66]. Ultimately, it will take a dedicated and educated global population to elimi-
nate rabies as a whole; until then, vaccinating animals and at-risk populations is the 
most efficient means of prevention.
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6. Conclusion
This chapter served to outline the diagnosis, clinical course, treatment, and 
prevention of the RNA virus RABV. A swift rabies’s diagnosis is imperative to ensure 
the patient’s greatest chance of survival. Clinicians may utilize many techniques 
such as MRI, rtPCR, FAT, FAVN, dRIT, and electron microscopy to diagnose 
patients before physical symptoms arise. The same methods can be used to confirm 
a diagnosis after the patient presents with symptoms if needed. Rabies can present 
in patients in the furious or paralytic form. Although these cause very different 
physical symptoms, the pathophysiology is very similar. Generally initiated by a bite 
or other wound, the virus will incubate in the myocytes nearest the entry point and 
replicate undetected for an average of 1–3 months. Eventually, the virus will infect a 
nerve cell and travel through axon transport to the CNS at which point it will cause 
encephalitis or paralysis. Once the virus has infiltrated the CNS, it is essentially 
incurable. However, if detected early, patients can receive PEP - a combination of 
active and passive immunization most frequently in the form of a cell culture vac-
cine and a dose of RIG. At this time, there are no antivirals considered to be effec-
tive for treating RABV. If the virus becomes established in the patient, the treatment 
plan is adjusted to ensure the most comfort for the patient and their loved ones. This 
most often consists of a variety of sedatives, pain management, antipyretics, and 
fluids. Due to the great lethality of RABV in humans, multiple global organizations 
have banded together to attempt to eradicate the modern world of the rabies virus. 
The Zero by 30 movement strives to implement a stepwise method to eliminate 
dog-mediated rabies cases worldwide by 2030. This is believed to be possible if 70% 
or more of the dog population is vaccinated against rabies. In combination with the 
vaccination goal, Zero by 30 also encourages countries to implement educational 
standards on rabies, bite prevention, and responsible pet ownership.
At this time, the community of RABV researchers need to be working to improve 
current treatment options in order to decrease the number of RABV-related deaths. 
This might be done by developing a mAb alternative to the too-expensive RIG 
options or finding an effective antiviral either currently on the market or newly 
developed. The release of additional rabies vaccines for humans would also help to 
lower the price and improve the accessibility in a way that would benefit the highly 
affected countries.
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